Glecaprevir/Pibrentasvir

Treatment for Acute Hepatitis C

Typical Dosage: 300 mg glecaprevir / 120 mg pibrentasvir once daily

Effectiveness

99%

Safety Score

70%

Clinical Trials

Participants

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Treatment Details

Dosage Range

300 mg glecaprevir / 120 mg pibrentasvir once daily

Time to Effect

Within 8 weeks of treatment completion

Treatment Duration

8 weeks

Evidence Quality

HIGH

Number Needed to Treat (NNT)

1(Treat 1 patients to see 1 additional successful outcome)

Number Needed to Harm (NNH)

100(Treat 100 patients to see 1 additional serious adverse event)

Confidence Score

95%confidence in effectiveness data

Health Economics

Annual Cost of Care

Drug Cost:$18,000

Monitoring:$1,000

Side Effect Mgmt:$200

Total Annual:$19,200

Cost-Effectiveness Analysis

Cost-Effectiveness Rating

EXCELLENT

ICER

$45,000/QALY

QALYs Gained

Outcome-Based Costs

Cost per Responder

$19,394

Cost per Remission

$19,394

Comparison vs Pegylated Interferon + Ribavirin

Cost Difference

$-15,800/year

Less expensive

QALY Difference

+2.50 QALYs

Better outcomes

Dominance

DOMINATESBetter + cheaper

Prescription Access Economics

Annual Societal Loss per Patient

$15,390

Cost of prescription-only barriers (visits, time, admin, price premium)

Physician Visit Cost

$250/year

Time Cost

$120/year

Travel + wait time

Insurance Admin Cost

$20/year

Prior auth, claims

Rx Price

$18,000/year

Potential OTC Price

$3,000/year

Estimated if OTC available

Risk Assessment

Misuse Risk

LOW

Missed Diagnosis Risk

LOW

Glecaprevir/Pibrentasvir Outcomes

for Acute Hepatitis C

Efficacy Outcomes

Overall Effectiveness

+99%

Response Rate

+99%

Remission Rate

+99%

Common Side Effects

Headache

+19%

Fatigue

+14%

Nausea

+9%

Diarrhea

+6%

Sources:

drugtopics.com

nih.gov

hcplive.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials

No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials

3 completed trials for Glecaprevir/Pibrentasvir in Acute Hepatitis C

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

NCT04903626COMPLETEDPHASE3

View Study

286 participants

INTERVENTIONAL

Chandler, United States +69 more

Started: Aug 24, 2021